Vytorin

This page shows the latest Vytorin news and features for those working in and with pharma, biotech and healthcare.

CETP inhibitor class finally dies as Merck abandons anacetrapib

ezetimibe) and sister product Vytorin (ezetimibe plus simvastatin) - into a blockbuster franchise.

Merck & Co's anacetrapib data fails to generate much excitement

selling Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) in this therapeutic area despite a small effect on cardiovascular outcomes.
FDA panel rejects cardiovascular outcomes claim for Vytorin

Merck &Co fail to convince regulator's advisors. Merck &Co has failed to convince an FDA advisory committee that labelling for its cholesterol-lowering drug Vytorin should include a claim of ... The trial started around 10 years ago - shortly after
Merck hopes for another Keytruda with new immunotherapy deal

But Merck has been hit by the on-going erosion to its cardiovascular and cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin).
Relief as study finds no cardiovascular risk with Januvia

Overall pharma sales fell 2% on the back of declines for cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as well as immunotherapeutic Remicade (infliximab) which is facing biosimilar competition in
Merck's ezetimibe has 'modest' benefit when added to statins

under way nine years ago - shortly after Vytorin was first launched onto the market. ... Undeterred, Merck has said it will now file for approval of updated labelling for Vytorin and Zetia based on the results of IMPROVE-IT next year.

More from news
Approximately 4 fully matching, plus 27 partially matching documents found.

Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

The pharma giant’s aim was to acquire the cholesterol inhibitor Vytorin, a product it had been hoping to develop before being been beaten to the finish line by its competitor.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Add my company

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
The evolution of real-world studies: How industry and regulators are using real-world data...